Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer/Aventis File For Exubera In Europe; No Timeline Yet On U.S. Submission

This article was originally published in The Pink Sheet Daily

Executive Summary

With extensive use of inhaled insulin expected "right out of the box," the development partners are focused on getting Exubera through, not to, regulatory agencies as quickly as possible, Pfizer CFO Shedlarz says.
Advertisement

Related Content

Exubera Inhaled Insulin Gets Favorable Committee Review In Europe
Exubera Inhaled Insulin Gets Favorable Committee Review In Europe
Exubera Inhaled Insulin User Fee Deadline Is January 2006
Exubera Inhaled Insulin User Fee Deadline Is January 2006
Sanofi-Aventis In Talks With Pfizer And P&G About Exubera, Actonel Deals
Sanofi-Aventis In Talks With Pfizer And P&G About Exubera, Actonel Deals
Kos Inhaled Insulin Comparable To Lantus In Phase IIa Trial, Firm Says
Kos Inhaled Insulin Comparable To Lantus In Phase IIa Trial, Firm Says
Lilly/Alkermes Inhaled Insulin To Enter Late-Stage Development
Novo Nordisk/Aradigm Inhaled Insulin Study For Type 1 Diabetes Raises Efficacy Concern

Topics

Advertisement
UsernamePublicRestriction

Register

PS059027

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel